Latest Conference Articles

US Needs Drug Negotiating Power, ASCO Study Concludes

Skylar Jeremias

May 31 2020

Cancer drug prices are rising in the United States and Europe, but European regulators negotiate drug prices, and the results are seen in pricing trends, investigators said in a presentation at the American Society of Clinical Oncology.

Higher Value Oncology Care Is Needed, VA Doctor Says at ASCO

Tony Hagen

May 30 2020

Devika Das, MBBS, reviews the evidence presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology, and concludes that some deep reforms are needed in oncology care to improve access.

Money and Control Influence Oncologists' Use of Biosimilars

Skylar Jeremias

May 30 2020

Abstracts presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology, revealed important data on physician prescribing of biosimilars and cost savings in the oncology space.

Prestige BioPharma's Trastuzumab Demonstrates Equivalence

Tony Hagen

May 29 2020

Prestige BioPharma of Singapore has successful clinical trials to support its bid to market a trastuzumab, based on findings presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.

Biosimilar Pegfilgrasim Cuts OCM Expense, ASCO Study Finds

Tony Hagen

May 29 2020

A study presented at ASCO20 Virtual demonstrated the power of biosimilar pegfilgrastim to lower costs in the Oncology Care Model (OCM), where pegfilgrastim expense amounts to 5.3% of the total cost of cancer care.

Part 1: NCCN Panelist Says Biosimilar Past Is Not Prologue

Skylar Jeremias

May 28 2020

Despite the United States’ slow start in biosimilar uptake, history shows that things can change, according to Michael Kolodziej, MD, who presented at the National Comprehensive Cancer Network (NCCN) 2020 Virtual Conference.

Part II: NCCN Panelists Take On Drug Rebates

Tony Hagen

May 22 2020

Drug rebates have survived despite the payment reforms imposed by the Medicare Modernization Act of 2003, and now payers are taking advantage of them, too, panelists noted at the National Comprehensive Cancer Network (NCCN) 2020 Virtual Annual Conference.

Part 1: NCCN Panel Discusses Patient Education on Biosimilars

Tony Hagen

May 22 2020

Patient preferences play a large role in the effort to get biosimilars into the mainstream of therapeutics, and education is often a struggle, panelists said at the National Comprehensive Cancer Network (NCCN) 2020 Virtual Annual Conference.

NCCN Study Lends Support for Safety and Efficacy Investigation

Tony Hagen

May 21 2020

A study of filgrastim and pegfilgrastim biosimilars demonstrated data are sufficiently large to support an investigation on the effectiveness of these agents.

Canada Grapples With Drug Price Escalation

Tony Hagen

May 21 2020

In July 2020 Canada will implement a series of reforms to help bring runaway drug prices under control, panelists said at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.